Skip to main content
Premium Trial:

Request an Annual Quote

UNC Chapel Hill Receives $1M from NIH to Provide Improved Proteomics Search Software

NEW YORK, Nov. 30 (GenomeWeb News) - Researchers at the University of North Carolina at Chapel Hill have received $1 million in funding from the US National Institutes of Health to further develop and make available proteomics software, NIH said today.


The three-year funding, from the National Center for Research Resources, will allow the scientists to improve their protein-identification software, called Genome Fingerprint Scanning, and distribute it more widely free of charge. The program is capable of matching protein mass-spectrometry data directly to unannotated or unfinished genome sequences.


Led by Morgan Giddings, the researchers plan to include peptide maps that users can browse overlaid on a genome, expand the list of searchable genomes, provide multi-genome searching, automate updates of the genome databases and distribution of the computing load, and include searching of multi-exon genes. Furthermore, they intend to make the program available on additional computing platforms.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.